The leukemia therapeutics treatment market valuation is US$ 15,246.7 million in 2023. In 2022, the value was US$ 14,504.8 million. The market is predicted to grow at a healthy CAGR of 7.1% from 2023 to 2033. The valuation of the leukemia therapeutics treatment market is anticipated to reach US$ 30,318.5 million by 2033.
Production Analysis of the Leukemia Therapeutics Treatment Market
| Attributes | Details |
|---|---|
| Leukemia Therapeutics Treatment Market Value for 2023 | US$ 15,246.7 million |
| Projected Market Value for 2033 | US$ 30,318.5 million |
| Value-based CAGR of Market for 2023 to 2033 | 7.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The leukemia therapeutics treatment market was valued at US$ 12034.0 million in 2017. The market progressed at a sluggish CAGR of 3.8% over the historical period from 2017 to 2022.
Due to the pandemic, an increasing number of resources were diverted towards Covid-19 treatment. As a result, leukemia therapeutics treatment suffered during the historical period. Nonetheless, the progress in different types of treatment and medicines continued. At the end of the historical period in 2022, the value of the leukemia therapeutics treatment market had reached US$ 14,504.8 million.
| Market Value (2017) | US$ 12,034.0 million |
|---|---|
| Historical CAGR (2017 to 2022) | 3.8% |
| Historical Market Valuation (2022) | US$ 14,504.8 million |
The leukemia therapeutics treatment market is estimated to be US$ 15,246.7 million in size in 2023. The progress of the market is predicted to be promising, with a CAGR of 7.1% over the forecast period.
The progress in the forecast period is set to outpace the progress in the historical period. As companies keep innovating with the help of technology, leukemia treatment is getting more effective. The cases of leukemia are also not slated to slow down over the forecast period, necessitating treatment for the disease.
Medical care is increasingly looked upon positively. Thus, leukemia therapeutics treatment is widely accepted to combat the disease. By 2033, the valuation of the leukemia therapeutics treatment market is expected to be US$ 30,318.5 million.
Principal Consultant
The leukemia therapeutics treatment market can be divided into four segments: treatment, molecule, mode of administration, and indication. By looking at the segments, the inclinations of the consumers become clear. The types of treatment and the way the consumers choose to receive treatment can also be seen.
Targeted drugs & immunotherapy are the preferred mode of treatment for patients. In 2022, targeted drugs & immunotherapy accounted for 57.2% of the market share by treatment.
Several drugs, such as Gleevec, Bosulif, and Sprycel, are in the leukemia treatment market. Many drugs are also under trial, with the Revumenib drug showing positive results while testing. Thus, drugs and immunotherapy are popular treatments. Chemotherapy is the preferred treatment method highly sought by patients in increasing numbers.
| Attributes | Details |
|---|---|
| Top Treatment | Targeted Drugs & Immunotherapy |
| Market Share in 2022 | 57.2% |
Small molecules are the most commonly used type of molecule in leukemia therapeutics treatment. In 2022, small molecules accounted for 55.6% of the market share by molecule.
The adoption of small molecules through inhibitors has been effective in leukemia treatment. Further, small molecule treatment has also led to fewer side effects in patients.
| Attributes | Details |
|---|---|
| Top Molecule | Small Molecule |
| Market Share in 2022 | 55.6% |
Injecting drugs is the preferred mode of administration for patients. In 2022, injectable treatment accounted for 61.7% of the market share by mode of administration.
Injections are commonly believed to act faster than doses of oral medicine. In leukemia treatment, consumers also opt for injectables as a mode for faster results.
| Attributes | Details |
|---|---|
| Top Mode of Administration | Injectable |
| Market Share in 2022 | 61.7% |
Chronic myeloid leukemia patients (CML) are the leading leukemia therapeutics treatment market. In 2022, the CML contributed to 43.2% of the market share by indication.
Effective CML treatment has drastically improved the survival rate. About 90% of the patients of CML are now expected to pull through the disease. Thus, the treatment of CML has earned an enhanced reputation.
| Attributes | Details |
|---|---|
| Top Indication | Chronic Myeloid Leukemia (CML) |
| Market Share in 2022 | 43.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
North America and Europe account for a large share of the market. In 2022, North America and Europe contributed 37.6% and 25.6% of the market share, respectively. The United States, in particular, held 33.3% of the global market share.
Countries in the Asia Pacific, like China, India, Japan, and South Korea, are slated to show substantial growth in the market over the coming years. Rapidly increasing population and economic development are leading factors in the growth of the market in the Asia Pacific region.
| Countries | CAGR |
|---|---|
| South Korea | 10.0% |
| China | 10.6% |
| Japan | 9.6% |
| India | 8.6% |
| Australia | 6.9% |
China is predicted to show incredible growth in the leukemia therapeutics treatment market during the forecast period. The Chinese market is expected to grow at a stellar CAGR of 10.6% through 2033.
Players in the Chinese market are increasingly focused on breakthroughs. Therefore, the nature of leukemia treatment in China is getting modernized. For example, in January 2022, Chinese scientists found a potential treatment for leukemia with the infusion of nanoparticles into the bloodstream.
South Korea is another Asian country with significant potential for the market. The South Korean market is forecasted to grow at an impressive CAGR of 10.0% over the forecast period.
Impressive healthcare facilities in South Korea attract even people from outside the country. Cancer treatment and research are also on the up in South Korea. Some expenses of cancer treatment are reimbursable in the country. Thus, the market is well-positioned in South Korea.
The market is expected to thrive in Japan as well. The Japanese market is expected to grow at a sturdy CAGR of 9.6% through 2033.
The average age in Japan is rising rapidly. Elderly people are prone to leukemia and form a huge section of the customer base for the leukemia therapeutics treatment industry. Therefore, Japan is rife with opportunities for the market.
Heavy investment is needed for innovations and breakthroughs in leukemia treatment. Thus, large companies with financial capacity hold a strong position in the market. However, with the aid of government and private funding, operations on a smaller scale also have scope.
Companies in the market have to wait for approvals to launch products into the market. Nonetheless, the players in the market are focused on having a wide range of products to treat different types of leukemia.
Recent Developments in the Leukemia Therapeutics Treatment Market
The leukemia therapeutics treatment market valuation is US$ 15,246.7 million in 2023.
The market size of leukemia therapeutics treatment is predicted to reach US$ 30,318.5 million by 2033.
Increasing cases of leukemia and a rise in the global aging population are stimulating the market demand.
The leukemia therapeutics treatment market is expected to progress at a CAGR of 7.1% from 2023 to 2033.
Ambit Biosciences Corporation, Biogen Idec, Inc., Ariad Pharmaceuticals, Inc., and Bristol-Myers Squibb are some of the prominent companies in the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market
4. Global Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Targeted Drugs
5.3.2. Chemotherapy
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Molecule Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Molecule Type, 2023 to 2033
6.3.1. Biologics
6.3.2. Small Molecules
6.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Molecule Type, 2023 to 2033
7. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Mode of Administration, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Mode of Administration, 2023 to 2033
7.3.1. Injectable
7.3.2. Oral
7.4. Y-o-Y Growth Trend Analysis By Mode of Administration, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Mode of Administration, 2023 to 2033
8. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Type
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
8.3.1. AML
8.3.2. CML
8.3.3. ALL
8.3.4. CLL
8.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
9. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Treatment Type
10.2.3. By Molecule Type
10.2.4. By Mode of Administration
10.2.5. By Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Molecule Type
10.3.4. By Mode of Administration
10.3.5. By Type
10.4. Key Takeaways
11. Latin America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Treatment Type
11.2.3. By Molecule Type
11.2.4. By Mode of Administration
11.2.5. By Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Molecule Type
11.3.4. By Mode of Administration
11.3.5. By Type
11.4. Key Takeaways
12. Western Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Treatment Type
12.2.3. By Molecule Type
12.2.4. By Mode of Administration
12.2.5. By Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Molecule Type
12.3.4. By Mode of Administration
12.3.5. By Type
12.4. Key Takeaways
13. Eastern Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Treatment Type
13.2.3. By Molecule Type
13.2.4. By Mode of Administration
13.2.5. By Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Molecule Type
13.3.4. By Mode of Administration
13.3.5. By Type
13.4. Key Takeaways
14. South Asia and Pacific Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Treatment Type
14.2.3. By Molecule Type
14.2.4. By Mode of Administration
14.2.5. By Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Molecule Type
14.3.4. By Mode of Administration
14.3.5. By Type
14.4. Key Takeaways
15. East Asia Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Treatment Type
15.2.3. By Molecule Type
15.2.4. By Mode of Administration
15.2.5. By Type
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment Type
15.3.3. By Molecule Type
15.3.4. By Mode of Administration
15.3.5. By Type
15.4. Key Takeaways
16. Middle East and Africa Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Treatment Type
16.2.3. By Molecule Type
16.2.4. By Mode of Administration
16.2.5. By Type
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Treatment Type
16.3.3. By Molecule Type
16.3.4. By Mode of Administration
16.3.5. By Type
16.4. Key Takeaways
17. Key Countries Industry Analysis and Outlook
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Treatment Type
17.1.2.2. By Molecule Type
17.1.2.3. By Mode of Administration
17.1.2.4. By Type
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Treatment Type
17.2.2.2. By Molecule Type
17.2.2.3. By Mode of Administration
17.2.2.4. By Type
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Treatment Type
17.3.2.2. By Molecule Type
17.3.2.3. By Mode of Administration
17.3.2.4. By Type
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Treatment Type
17.4.2.2. By Molecule Type
17.4.2.3. By Mode of Administration
17.4.2.4. By Type
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Treatment Type
17.5.2.2. By Molecule Type
17.5.2.3. By Mode of Administration
17.5.2.4. By Type
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Treatment Type
17.6.2.2. By Molecule Type
17.6.2.3. By Mode of Administration
17.6.2.4. By Type
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Treatment Type
17.7.2.2. By Molecule Type
17.7.2.3. By Mode of Administration
17.7.2.4. By Type
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Treatment Type
17.8.2.2. By Molecule Type
17.8.2.3. By Mode of Administration
17.8.2.4. By Type
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Treatment Type
17.9.2.2. By Molecule Type
17.9.2.3. By Mode of Administration
17.9.2.4. By Type
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Treatment Type
17.10.2.2. By Molecule Type
17.10.2.3. By Mode of Administration
17.10.2.4. By Type
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Treatment Type
17.11.2.2. By Molecule Type
17.11.2.3. By Mode of Administration
17.11.2.4. By Type
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Treatment Type
17.12.2.2. By Molecule Type
17.12.2.3. By Mode of Administration
17.12.2.4. By Type
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Treatment Type
17.13.2.2. By Molecule Type
17.13.2.3. By Mode of Administration
17.13.2.4. By Type
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Treatment Type
17.14.2.2. By Molecule Type
17.14.2.3. By Mode of Administration
17.14.2.4. By Type
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Treatment Type
17.15.2.2. By Molecule Type
17.15.2.3. By Mode of Administration
17.15.2.4. By Type
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Treatment Type
17.16.2.2. By Molecule Type
17.16.2.3. By Mode of Administration
17.16.2.4. By Type
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Treatment Type
17.17.2.2. By Molecule Type
17.17.2.3. By Mode of Administration
17.17.2.4. By Type
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Treatment Type
17.18.2.2. By Molecule Type
17.18.2.3. By Mode of Administration
17.18.2.4. By Type
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Treatment Type
17.19.2.2. By Molecule Type
17.19.2.3. By Mode of Administration
17.19.2.4. By Type
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Treatment Type
17.20.2.2. By Molecule Type
17.20.2.3. By Mode of Administration
17.20.2.4. By Type
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Treatment Type
17.21.2.2. By Molecule Type
17.21.2.3. By Mode of Administration
17.21.2.4. By Type
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Treatment Type
17.22.2.2. By Molecule Type
17.22.2.3. By Mode of Administration
17.22.2.4. By Type
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2022
17.23.2.1. By Treatment Type
17.23.2.2. By Molecule Type
17.23.2.3. By Mode of Administration
17.23.2.4. By Type
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Treatment Type
18.3.3. By Molecule Type
18.3.4. By Mode of Administration
18.3.5. By Type
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Novartis International AG
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. GlaxoSmithKline Pharmaceuticals Limited
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Roche
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Bristol-Myers Squibb
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Genmab A/S
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Celgene Corporation
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Biogen
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Pfizer
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Ambit Biosciences Corporation
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Ariad Pharmaceuticals, Inc
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Leukemia Therapeutics Treatment Market
